Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

10.1K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
10.1K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

3.8K
3.8K
Non-LTR Retrotransposons03:18

Non-LTR Retrotransposons

13.9K
As the name suggests, non-LTR retrotransposons lack the long terminal repeats characteristic of the LTR retrotransposons. Additionally, both LTR and non-LTR retrotransposons use distinct mechanisms of mobilization. Non-LTR retrotransposons are further divided into two classes - Long interspersed nuclear elements (LINEs) and short interspersed nuclear elements (SINEs), both of which occur abundantly in most mammals, including humans. Some of the active non-LTR retrotransposons in humans are L1...
13.9K
RNA Splicing01:32

RNA Splicing

61.2K
Splicing is the process by which eukaryotic RNA is edited before its translation into protein. The RNA strand transcribed from eukaryotic DNA is called the primary transcript. The primary transcripts that become mRNAs are called precursor messenger RNAs (pre-mRNAs). Eukaryotic pre-mRNA contains alternating sequences of exons and introns. Exons are nucleotide sequences that code for proteins, whereas introns are the non-coding regions. In RNA splicing, introns are removed and exons are bonded...
61.2K
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

6.6K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
6.6K
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

5.9K
5.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

YAU-RCC Insights from ASCO GU 2026: emerging advances in renal cell carcinoma management.

Minerva urology and nephrology·2026
Same author

Prognostic relevance and molecular correlates of Claudin-1 expression in pancreatic neuroendocrine tumors.

Human pathology·2026
Same author

What should the urologist know on the management of kidney cancer in patients with Von Hippel-Lindau syndrome? Recommendations of the European Association of Urology (EAU) Young Academic Urologists (YAU) Renal Cancer Working Group.

World journal of urology·2026
Same author

Profiling of desmoid tumors reveals frequent mutations in chromatin-remodeling genes and identifies an Immune-myogenic subtype.

European journal of cancer (Oxford, England : 1990)·2026
Same author

Re: Circulating Kidney Injury Molecule-1 (KIM-1) and Association with Outcome to Adjuvant Immunotherapy in Renal Cell Carcinoma.

European urology·2026
Same author

MiT fusions, TSC1-TSC2 divergence, and stem-like programs reveal distinct origins and vulnerabilities in PEComa.

Nature communications·2026

Related Experiment Video

Updated: Mar 19, 2026

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells
07:23

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Published on: May 30, 2025

1.3K

Cancer subtypes classification using long non-coding RNA.

Ronan Flippot1, Gabriel G Malouf1, Xiaoping Su2

  • 1Groupe Hospitalier Pitié-Salpêtrière, Department of Medical Oncology, University Pierre and Marie Curie (Paris VI), Institut Universitaire de Cancérologie, AP-HP, Paris, France.

Oncotarget
|June 25, 2016
PubMed
Summary

Long non-coding RNAs (lncRNAs) are emerging as key players in cancer heterogeneity. Studying lncRNA expression profiles will help classify cancer subtypes and identify prognostic biomarkers.

Keywords:
cancerclassificationlncRNAslong non-coding RNAsprognosis

More Related Videos

Author Spotlight: RNA FISH for Locating lncRNA-SNHG6 in Osteosarcoma Cells
05:27

Author Spotlight: RNA FISH for Locating lncRNA-SNHG6 in Osteosarcoma Cells

Published on: June 16, 2023

2.5K
Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

6.9K

Related Experiment Videos

Last Updated: Mar 19, 2026

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells
07:23

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Published on: May 30, 2025

1.3K
Author Spotlight: RNA FISH for Locating lncRNA-SNHG6 in Osteosarcoma Cells
05:27

Author Spotlight: RNA FISH for Locating lncRNA-SNHG6 in Osteosarcoma Cells

Published on: June 16, 2023

2.5K
Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

6.9K

Area of Science:

  • Oncology
  • Molecular Biology
  • Genomics
  • Epigenetics

Background:

  • Inter-tumor heterogeneity complicates cancer evolution despite similar pathological features.
  • Genomic studies have advanced tumor subtyping by identifying driver mutations.
  • Epigenetics and long non-coding RNAs (lncRNAs) are increasingly recognized as contributors to tumor heterogeneity.

Purpose of the Study:

  • To discuss the significance of lncRNAs as prognostic and predictive biomarkers in cancer.
  • To explore the impact of lncRNA-based classification on emerging cancer subtypes.
  • To highlight the role of lncRNA expression profiles in understanding cancer progression.

Main Methods:

  • Review of current evidence on lncRNA involvement in cancer progression.
  • Analysis of epigenetic regulation mechanisms mediated by lncRNAs.
  • Examination of lncRNA interactions with other RNA subtypes and oncogenic pathways.

Main Results:

  • Modifications in lncRNA expression profiles are linked to cancer progression.
  • lncRNAs influence cancer through epigenetic regulation and activation of pro-oncogenic pathways.
  • lncRNA expression profiles show potential for defining novel cancer subtypes.

Conclusions:

  • lncRNA expression profiling is crucial for future cancer subtype classification.
  • lncRNAs hold significant promise as biomarkers for cancer prognosis and progression.
  • Emerging cancer classifications based on lncRNAs may refine patient stratification and treatment strategies.